Proksokarpin - instructions for use, dose, side effects, contraindications

Similar drugsTo uncover

Dosage form: & nbspeye drops

Composition:

1 ml of the solution contains:

active substances: pilocarpine hydrochloride 10.00 mg, butylamine hydroxypropoxyphenoxymethyl methyl oxadiazole hydrochloride 10.00 mg;

Excipients: citric acid 5.20 mg, monohydrate (or citric acid in terms of citric acid monohydrate) sodium citrate 7.45 mg, sodium pentasecyl chloride chloride 2.00 mg, benzethonium chloride 0.10 mg, water purified to 1 ml.

Description:Transparent, colorless or slightly colored liquid.

Pharmacotherapeutic group:antiglaucoma

ATX: & nbsp

Other antiglaucoma drugs

Pharmacodynamics:

Butylamin hydroxypropoxyphenoxymethyl methyloxadiazole is a nonselective beta-blocker that also has a selective alpha-adrenoceptor blocking effect. Oppresses the production of watery moisture. Pilocarpine - m-cholinomimetic, causes a contraction of the circular muscle (miosis) and ciliary muscle (spasm of accommodation). Reduction of the circular muscle (miosis) leads to a shift in the basal part of the iris from the angle of the anterior chamber of the eye, which facilitates the opening of the helmet canal and fountain spaces with closed-angle glaucoma. Reduction of the ciliary muscle (spasm of accommodation) leads to the opening of the helmet canal and trabecular gaps in open-angle glaucoma. Due to these processes, the outflow of aqueous humor from the anterior chamber of the eye increases with a further decrease in intraocular pressure.The pharmacological action of the combined preparation "Proxocarpine® eye drops" is due to the additive effect.

Pharmacokinetics:

The onset of the effect - 1 hour after instillation, reaches a maximum in 4-6 hours and lasts for more than 24 hours. The drug does not have a damaging effect on the eye tissue.

Indications:

- Various forms of glaucoma (primary open-angle and closed-angle, congenital, juvenile, secondary);

- insufficient effectiveness of monotherapy Proxodolol® or Pilocarpine.

Contraindications:

Individual hypersensitivity to one of the components of the drug; bronchial asthma, bronchial obstructive pulmonary disease; Chronic heart failure, bradycardia, arterial hypotension, atrioventricular blockade II-III degree; pregnancy; inflammation of the anterior part of the choroid of the eye (iris, ciliary body), iritis, iridocyclitis and other conditions in which the pupil narrowing is not recommended (for example, after surgery on the eye, except when it is necessary to narrow the pupil immediately after surgery,to prevent the formation of synechia); children's age till 18 years; retinal detachment, including history, as well as conditions predisposing to detachment of the retina.

If you have one of the listed diseases, before taking the drug always consult a doctor.

Carefully:

Myopia of a high degree in young patients, cardiogenic shock, type I diabetes, peptic ulcer and duodenal ulcer.

During the period of treatment, it is not recommended to wear soft contact lenses. When using hard lenses, they should be removed before instillation and re-dressed 15-20 minutes after the instillation of the drug.

Treatment should be carried out with regular monitoring of intraocular pressure.

If you have one of the listed diseases, or you wear lenses, before taking the drug always consult a doctor.

Pregnancy and lactation:

Do not use during pregnancy and during lactation, since there is no experience with the use of the drug during this period.

The use of proksokarpina® for the treatment of pregnant and lactating mothers is possible for the prescribing physician if the expected curative effect exceeds the risk of possible side effectseffects.

Dosing and Administration:

Bury in the conjunctival cavity 1 drop 2 times a day.

Side effects:

Burning, miosis, spasm of accommodation, lacrimation, short-term vision impairment due to pupil narrowing, eye pain, allergic conjunctivitis, superficial keratitis, dermatitis of the eyelid skin, reversible lens opacity.

Headache, dizziness, weakness, nausea, rhinorrhea, allergic reactions (local or generalized eczema, urticaria).

Rarely observed bronchospasm, drooling, slowing heart rate, atrioventricular blockade, lowering blood pressure.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, inform the doctor about it.

Overdose:

Symptoms: nausea, increased salivation, sweating, bradycardia, bronchospasm, lowering blood pressure.

In case of accidental ingestion, poisoning is possible, manifested by a significant increase in m-cholinomimetic effects, including the development of severe heart failure and bronchoconstriction.

Treatment symptomatic. Gastric lavage, monitoring of heart rate, blood pressure, respiratory function. Atropine can be used as a specific antidote. With severe bradycardia due to an overdose of parasympathomimetics, 0.5-2 mg of atropine is administered parenterally.

Interaction:

Antagonists pilocarpine, which is part of the drug, are atropine and other m-anticholinergic agents.

With simultaneous use with adrenomimetics, mutual antagonism of action (per pupil diameter) can be observed.

The hypotensive effect on the level of intraocular pressure is enhanced by simultaneous use with carbonic anhydrase inhibitors.

Timolola maleate and phenylephrine (reduce the production of intraocular fluid) potentiate a decrease in intraocular pressure.

M-cholinomimetic activity of pilocarpine is reduced by tricyclic antidepressants, phenothiazine derivatives, chlorprotixen, clozapine; strengthens with anticholinesterase agents.

It is possible to develop bradycardia and lower blood pressure during general anesthesia with fluorotan.

Butylamine hydroxypropoxyphenoxymethyl methyl oxadiazole, which is part of the drug, increases the effect of clonidine on intraocular pressure.

With the simultaneous administration of systemic alpha or beta-blockers, there is a mutual enhancement of their action.

If you are taking any medications, always consult your doctor before taking proksocarpine.

Special instructions:

There is no information.

Effect on the ability to drive transp. cf. and fur:Patients who, after instillation, lose their clear vision, it is not recommended to drive a car or work with a complex technique that requires clear vision immediately after instillation of the drug.

Form release / dosage:

Eye drops.

Packaging:

1, 5 ml, 2 ml or 5 ml in a tube-dropper polymer.

1, 2, 4, 5 or 10 tubes with IV instructions are placed in a pack of cardboard.

5 ml or 10 ml in the bottle-dropper polymer.

1 or 2 vials of a dropper with instructions for the use of the drug are placed in a pack of cardboard.

The text of the instruction for the use of a tube-dropper or a bottle-dropper is applied to the pack.

5 ml into bottles from a glass tube.

1 bottle complete with a lid-dropper in a sterile version and instruction on the use of the drug is placed in a pack of cardboard.

Storage conditions:

In the dark place at a temperature of no higher than 15 ° C for the drug in a tube-droppers and a bottle of droppers.

In the dark place at a temperature of no higher than 25 ° C for the drug in glass vials.

Keep out of the reach of children.

Shelf life:

2 years.

Shelf life after the opening - 1 month.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LS-001562

Date of registration:18.04.2013

The owner of the registration certificate:MOSCOW ENDOCRINE FACTORY, FSUE MOSCOW ENDOCRINE FACTORY, FSUE Russia

Manufacturer: & nbsp

MOSCOW ENDOCRINE FACTORY, FSUE Russia

Representation: & nbspMOSCOW ENDOCRINE FACTORY FGUP MOSCOW ENDOCRINE FACTORY FGUP Russia

Information update date: & nbsp03.01.2016

Illustrated instructions

Instructions

Proksokarpin® (Proxocarpine®)